Payment overview · 2025
General Payments
$405.67
24 reported records · 7 companies
Healthcare provider profile · identity verified
Steven R Paulmeyer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OMAHA, NE · NPI 1982041802
Verified facts
What the public records show
CMS Open Payments records show Steven R Paulmeyer, MD received $405.67 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $181.78 | 44.8% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.03 | 15.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.84 | 13.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.99 | 11.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.35 | 7.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.95 | 3.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.73 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.67 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.04 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.81 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.84 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.32 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1164 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 798 | 156 |
| Losartan Potassium | Losartan Potassium | 760 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 642 | 105 |
| Omeprazole | Omeprazole | 582 | 112 |
| Potassium Chloride | Potassium Chloride | 445 | 75 |
| Furosemide | Furosemide | 441 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 436 | 76 |
| Lisinopril | Lisinopril | 435 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 422 | 96 |
| Metformin Hcl | Metformin Hcl | 416 | 79 |
| Gabapentin | Gabapentin | 395 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 336 | 65 |
| Sertraline Hcl | Sertraline Hcl | 300 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 262 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 40 |
| Carvedilol | Carvedilol | 245 | 47 |
| Trazodone Hcl | Trazodone Hcl | 224 | 40 |
| Montelukast Sodium | Montelukast Sodium | 207 | 32 |
| Xarelto | Rivaroxaban | 194 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 46 |
| Glimepiride | Glimepiride | 172 | 31 |
| Tramadol Hcl | Tramadol Hcl | 167 | 41 |
| Allopurinol | Allopurinol | 163 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 30 |
| Meloxicam | Meloxicam | 148 | 40 |
| Jardiance | Empagliflozin | 141 | 26 |
| Spironolactone | Spironolactone | 141 | 35 |
| Warfarin Sodium | Warfarin Sodium | 141 | 19 |
| Simvastatin | Simvastatin | 137 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 37 |
| Ozempic | Semaglutide | 127 | 20 |
| Eliquis | Apixaban | 126 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 33 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 117 | 116 |
| Pregabalin | Pregabalin | 108 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 23 |
| Prednisone | Prednisone | 102 | 59 |
| Alendronate Sodium | Alendronate Sodium | 101 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | suppressed |
| Finasteride | Finasteride | 97 | 17 |
| Buspirone Hcl | Buspirone Hcl | 94 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 17 |
| Alprazolam | Alprazolam | 84 | 23 |
| Metformin Hcl Er | Metformin Hcl | 84 | 26 |
| Propranolol Hcl | Propranolol Hcl | 83 | suppressed |
| Atenolol | Atenolol | 81 | 17 |
| Donepezil Hcl | Donepezil Hcl | 81 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 17 |
| Lorazepam | Lorazepam | 76 | 19 |
| Famotidine | Famotidine | 73 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 67 | 51 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | suppressed |
| Bupropion Xl | Bupropion Hcl | 64 | 15 |
| Celecoxib | Celecoxib | 64 | suppressed |
| Clonazepam | Clonazepam | 64 | 17 |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Mirtazapine | Mirtazapine | 62 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 58 | suppressed |
| Lamotrigine | Lamotrigine | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 17 |
| Ketoconazole | Ketoconazole | 53 | 14 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 12 |
| Torsemide | Torsemide | 48 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 19 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Naproxen | Naproxen | 43 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Cephalexin | Cephalexin | 40 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 36 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Loperamide | Loperamide Hcl | 34 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 12 |
| Risperidone | Risperidone | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Trimethoprim | Trimethoprim | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Nystatin | Nystatin | 22 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Austedo | Deutetrabenazine | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.67 · 24 records | ABBVIE INC. | ABRYSVO, COMIRNATY, ELIQUIS, EVENITY, FANAPT, LEQVIO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error